1. Home
  2. PROF vs ELDN Comparison

PROF vs ELDN Comparison

Compare PROF & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PROF
  • ELDN
  • Stock Information
  • Founded
  • PROF N/A
  • ELDN 2004
  • Country
  • PROF Canada
  • ELDN United States
  • Employees
  • PROF N/A
  • ELDN N/A
  • Industry
  • PROF Medical/Dental Instruments
  • ELDN Biotechnology: Pharmaceutical Preparations
  • Sector
  • PROF Health Care
  • ELDN Health Care
  • Exchange
  • PROF Nasdaq
  • ELDN Nasdaq
  • Market Cap
  • PROF 149.7M
  • ELDN 178.4M
  • IPO Year
  • PROF N/A
  • ELDN N/A
  • Fundamental
  • Price
  • PROF $5.86
  • ELDN $3.75
  • Analyst Decision
  • PROF Strong Buy
  • ELDN Strong Buy
  • Analyst Count
  • PROF 1
  • ELDN 2
  • Target Price
  • PROF $11.00
  • ELDN $12.50
  • AVG Volume (30 Days)
  • PROF 34.8K
  • ELDN 849.2K
  • Earning Date
  • PROF 08-07-2025
  • ELDN 08-18-2025
  • Dividend Yield
  • PROF N/A
  • ELDN N/A
  • EPS Growth
  • PROF N/A
  • ELDN N/A
  • EPS
  • PROF N/A
  • ELDN N/A
  • Revenue
  • PROF $11,862,000.00
  • ELDN N/A
  • Revenue This Year
  • PROF $71.17
  • ELDN N/A
  • Revenue Next Year
  • PROF $134.25
  • ELDN N/A
  • P/E Ratio
  • PROF N/A
  • ELDN N/A
  • Revenue Growth
  • PROF 75.01
  • ELDN N/A
  • 52 Week Low
  • PROF $3.90
  • ELDN $2.38
  • 52 Week High
  • PROF $11.42
  • ELDN $5.54
  • Technical
  • Relative Strength Index (RSI)
  • PROF 47.74
  • ELDN 70.21
  • Support Level
  • PROF $5.54
  • ELDN $3.63
  • Resistance Level
  • PROF $5.87
  • ELDN $3.93
  • Average True Range (ATR)
  • PROF 0.25
  • ELDN 0.22
  • MACD
  • PROF -0.04
  • ELDN 0.04
  • Stochastic Oscillator
  • PROF 33.09
  • ELDN 74.19

About PROF Profound Medical Corp.

Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.

About ELDN Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.

Share on Social Networks: